June 27, 2019
Today, approximately 12 percent of the global population experiences migraine attacks. And more than one third of these people have…
June 27, 2019
“Restrictive insurance policies keep patients from the very medications that can prevent and treat [headache and migraine disease],” asserts the…
June 25, 2019
The introduction of a new treatment is a boon for any disease state.
June 20, 2019
“It was so bad. It just wouldn’t quit.” Sara, a new patient, was sitting in my office describing a migraine attack that had led to a recent hospitalization.
June 13, 2019
A seasonal respiratory virus that threatens the lives of infants also can have a ripple effect on caregivers, families and workplaces, a new data analysis demonstrates.
June 11, 2019
It’s that time again. The controversial Institute for Clinical and Economic Review is examining its value framework, the rules and assumptions it uses to analyze new drugs’ cost effectiveness.
June 11, 2019
When it comes to shared medical decision-making, European patients with rheumatoid arthritis are open to ideas.
June 10, 2019
The conclusions from ICER’s cost-effectiveness evaluations can impact patients’ access to needed treatments. It is imperative, consequently, that ICER’s value assessment…
June 7, 2019
Elated. Nervous. Hopeful. That’s how thousands of cystic fibrosis patients felt upon hearing last week’s news: the Food and Drug Administration will soon review a new triple combination therapy that could drastically improve their quality of life.
June 5, 2019
The Institute for Clinical and Economic Review is dashing patients’ hopes yet again.
